Ensartinib
Mutation
Sun Yat-sen UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
11 Active assets in the Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus Fudan University | Phase 3 | B |
Glecirasib Sun Yat-sen University | Phase 2 | CCC |
gsk1120212 Sun Yat-sen University | Phase 2 | CCC |
VOLITINIB Sun Yat-sen University | Phase 2 | CCC |
Pralsetinib, trans- Sun Yat-sen University | Phase 2 | CCC |
View all 12 →
Same molecule, other indications
Ensartinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →